US removes strictest warnings from three menopause estrogen patches
The US Food and Drug Administration (FDA) has approved removing some of the strictest warnings from the labels of three estrogen patches for menopause symptoms, the Department of Health and Human Services (HHS) said on Friday, 30 October 2026. The patches deliver estradiol through the skin.
The change removes statements about cardiovascular disease, breast cancer and probable dementia from the boxed warning — the strongest warning the FDA puts on a medicine’s label. HHS said the statements were outdated after a re-examination of the scientific literature and updated information on the treatments’ benefits and risks. It did not name the three products or the two companies behind them.
In February 2026, the FDA approved similar labelling changes for six menopause hormone therapy products, and 29 drug companies have submitted proposed labelling changes since November 2025. HHS also said estradiol patch output has doubled over the past 12 months as manufacturers added capacity and extra shifts, and that it sees no imminent risk of a nationwide shortage, although some women have had difficulty finding their usual product locally.
Why it matters
Menopause patches ease symptoms such as hot flushes, night sweats and sleep problems, but strong warnings have put many women and doctors off hormone therapy. HHS Secretary Robert F. Kennedy Jr. called removing the statements “a major victory for women’s health”. The decision has also drawn criticism: The Guardian reported concerns from experts about the lack of a formal advisory committee meeting and the limited detail given about the evidence behind the change. The change does not mean the treatment is risk-free, and the labels still carry risk information, so the decision remains one for each woman to make with her doctor.
What happens next
The FDA said it is working through the remaining labelling changes submitted by drug companies. It is also exploring whether vaginal estrogen products could one day be sold without a prescription, but no such change has been approved — that would need FDA approval and evidence that people can choose and use the product safely without a healthcare professional. HHS advised women who cannot find their usual patch to speak to their pharmacist or healthcare provider, who may be able to suggest an available alternative.
This article is for general information and education only. It is not legal or financial advice.
Sources
- https://www.hhs.gov/press-room/fda-advances-menopause-care-hormone-therapy-labeling-access.html (U.S. Department of Health and Human Services, 30 October 2026)
- https://963jackfm.com/2026/10/30/us-health-department-to-remove-broad-black-box-warning-from-three-estrogen-patch-products/ (Reuters, 30 October 2026)
- https://www.healio.com/news/womens-health-ob-gyn/20261030/hhs-updates-safety-labels-for-three-more-menopausal-hormone-therapy-products (Healio, 30 October 2026)
- https://www.fdaweb.com/fda-removes-more-estrogen-patch-boxed-warnings/ (FDAWeb, 30 October 2026)
